A review on epidermal growth factor receptor's role in breast and non-small cell lung cancer
Epithelial growth factor receptor (EGFR) is a cell surface transmembrane receptor that
mediates the tyrosine signaling pathway to carry the extracellular messages inside the cell …
mediates the tyrosine signaling pathway to carry the extracellular messages inside the cell …
Pyrotinib in HER2-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study
C Zhou, X Li, Q Wang, G Gao, Y Zhang… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE Targeted therapies against non–small-cell lung cancer (NSCLC) harboring
HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of …
HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of …
Non‐invasive molecular imaging for preclinical cancer therapeutic development
AC O'farrell, SD Shnyder, G Marston… - British journal of …, 2013 - Wiley Online Library
Molecular and non‐invasive imaging are rapidly emerging fields in preclinical cancer drug
discovery. This is driven by the need to develop more efficacious and safer treatments, the …
discovery. This is driven by the need to develop more efficacious and safer treatments, the …
[HTML][HTML] PLEKHM1 regulates autophagosome-lysosome fusion through HOPS complex and LC3/GABARAP proteins
DG McEwan, D Popovic, A Gubas, S Terawaki… - Molecular cell, 2015 - cell.com
The lysosome is the final destination for degradation of endocytic cargo, plasma membrane
constituents, and intracellular components sequestered by macroautophagy. Fusion of …
constituents, and intracellular components sequestered by macroautophagy. Fusion of …
[HTML][HTML] Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks
Crosstalk and complexity within signaling pathways and their perturbation by oncogenes
limit component-by-component approaches to understanding human disease. Network …
limit component-by-component approaches to understanding human disease. Network …
Poziotinib for Patients With HER2 Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial
YY Elamin, JP Robichaux, BW Carter… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Targeted therapies against non–small-cell lung cancer (NSCLC) harboring
HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of …
HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of …
[HTML][HTML] Derivation of a new model of lung adenocarcinoma using canine lung cancer organoids for translational research in pulmonary medicine
Y Shiota, M Elbadawy, K Suzuki, R Tsunedomi… - Biomedicine & …, 2023 - Elsevier
Canine primary lung cancer (cPLC) is a rare malignant tumor in dogs, and exhibits poor
prognosis. Effective therapeutic drugs against cPLC have not been established yet. Also …
prognosis. Effective therapeutic drugs against cPLC have not been established yet. Also …
FOXO3a represses VEGF expression through FOXM1-dependent and-independent mechanisms in breast cancer
CT Karadedou, AR Gomes, J Chen, M Petkovic, KK Ho… - Oncogene, 2012 - nature.com
Vascular endothelial growth factor (VEGF) has a central role in breast cancer development
and progression, but the mechanisms that control its expression are poorly understood …
and progression, but the mechanisms that control its expression are poorly understood …
[HTML][HTML] Macrophages M2 polarization is involved in lapatinib-mediated chemopreventive effects in the lung cancer
M2 polarized tumor-associated macrophages (TAMs) have a multifunctional role in cancer
initiation, progression, metastasis, and contribute to chemotherapeutic resistance. Therefore …
initiation, progression, metastasis, and contribute to chemotherapeutic resistance. Therefore …
Design, synthesis, and docking of novel thiazolidine‐2, 4‐dione multitarget scaffold as new approach for cancer treatment
NS Hanafy, NAAM Aziz, SSA El‐Hddad… - Archiv der …, 2023 - Wiley Online Library
Abstract Novel thiazolidine‐2, 4‐diones have been developed and estimated as conjoint
inhibitors of EGFRT790M and VEGFR‐2 against HCT‐116, MCF‐7, A549, and HepG2 cells …
inhibitors of EGFRT790M and VEGFR‐2 against HCT‐116, MCF‐7, A549, and HepG2 cells …